Panbio Covid-19 Ag (nasopharyngeal)
Der Panbio Covid-19 Ag von Abbott ist ein professioneller SARS-CoV-2 Antigen-Schnelltest für den Einsatz am Point of Care. Der immunologische Kassettentest dient dem qualitativen Nachweis des viralen Nukleokapsidproteins aus nasopharyngealen Abstrichen und liefert innerhalb von 15 Minuten ein klar ablesbares Ergebnis. Durch die schnelle Verfügbarkeit, die hohe Spezifität und die einfache Handhabung eignet sich der Test besonders für klinische Einrichtungen, in denen eine sofortige Entscheidung über weitere diagnostische oder therapeutische Schritte erforderlich ist.
Der Panbio Covid-19 Ag basiert auf einem chromatographischen, immunologischen Lateral-Flow-Verfahren. Antikörper-Goldkonjugate binden spezifisch an SARS-CoV-2-Antigene und erzeugen bei Vorliegen des Virus eine sichtbare Testlinie. Eine Kontrolllinie zeigt die korrekte Testdurchführung an. Die Probe wird nach Extraktion als definierte Tropfenmenge auf die Kassette aufgebracht, die Auswertung erfolgt zwischen 15 und 20 Minuten. Die klare visuelle Darstellung unterstützt eine sichere und schnelle Interpretation im klinischen Alltag.
- Kliniken und Notaufnahmen
- Medizinische Ambulanzen und mobile Versorgung
- Pflegeeinrichtungen und Reha-Zentren
- Strukturierte Screenings in medizinischen Organisationen
- Einsatzsituationen, die schnelle Ergebnisse ohne Laborinfrastruktur erfordern
- Verdacht auf eine akute SARS-CoV-2-Infektion
- Symptomatische Patient:innen in den ersten Krankheitstagen
- Triage in Notfall- und Aufnahmeeinheiten
- Ergänzende Entscheidungsunterstützung bei begrenzten PCR-Kapazitäten
- Schnelltests bei Ausbruchsgeschehen in Einrichtungen des Gesundheitswesens
- Ergebnis in nur 15 Minuten
- Hohe diagnostische Genauigkeit für den professionellen Einsatz
- Einfache, standardisierte Durchführung mit klaren Ablesekriterien
- Stabile Testperformance auch in dezentralen POCT-Umgebungen
- Minimiertes Risiko der Probenexposition durch integriertes Extraktionsröhrchen
- Gut geeignet für größere Testvolumina und repetitive Screeningprozesse
Im Vergleich zu vielen Antigen-POCTs überzeugt der Panbio Covid-19 Ag durch evaluierte Performance, klare Ergebnisinterpretation und eine robuste Testarchitektur. Die Kombination aus hoher Spezifität, kurzer Ergebniszeit und validierter Testqualität macht ihn zu einer verlässlichen Option für medizinische Einrichtungen, die schnelle und gleichzeitig präzise COVID-19-Diagnostik benötigen.
Parameterübersicht
Es ist möglich, dass bestimmte berechnete Parameter nicht angegeben sind.
Testübersicht (1)
Panbio Covid-19 Ag (nasopharyngeal)
Panbio Covid-19 Ag (nasopharyngeal)
Studien & Produktdokumente
Decreased Sensitivity of Rapid Antigen Test Is Associated with a Lower Viral Load of Omicron than Delta SARS-CoV-2 Variant.
"EQA schemes can provide valuable data to inform participants about weaknesses in their testing process or methods and support ongoing assay evaluations for regulatory approval or post-market surveillance."
Low sensitivity of the COVID-19 antigen test (PANBIO™ COVID-19 Ag rapid test) to detect asymptomatic infections in health personnel of the National Institute of Respiratory Diseases.
Avoiding False-Positive SARS-CoV-2 Rapid Antigen Test Results with Point-of-Care Molecular Testing on Residual Test Buffer.
Investigating the Sensitivity of Nasal or Throat Swabs: Combination of Both Swabs Increases the Sensitivity of SARS-CoV-2 Rapid Antigen Tests.
Utility of SARS-CoV-2 rapid antigen testing for patient triage in the emergency department: A clinical implementation study in Melbourne, Australia.
Zimbabwe's emergency response to COVID-19: Enhancing access and accelerating COVID-19 testing as the first line of defense against the COVID-19 pandemic.
Screening for SARS-CoV-2 Infection in Students at the Medical University of Warsaw, Poland Between November 15 and December 10, 2021 Using a Single Lateral Flow Test, the Panbio™ COVID-19 Ag Rapid Test.
Feasibility of a refurbished shipping container as a transportable laboratory for rapid SARS-CoV-2 diagnostics.
Comparison of the Performance of the PanBio COVID-19 Antigen Test in SARS-CoV-2 B.1.1.7 (Alpha) Variants versus non-B.1.1.7 Variants.
Limitations of point-of-care testing for low SARS CoV-2 loads: Insights for future pandemics.
This study evaluated ten SARS-CoV-2 rapid diagnostic tests across Nigeria, finding that while antigen-based kits [LumiraDx SARS-CoV-2 Ag, Abbott Panbio COVID-19 Ag, Lifotronic SARS-CoV-2 Antigen, MP Rapid SARS-CoV-2 Antigen Card, Mologic COVID-19 Antigen Rapid Diagnostic Test, SGTi-flex COVID-19 Ag] outperform antibody tests [SGTi-flex COVID-19 IgM/IgG, SD Biosensor COVID-19 IgM/IgG Combo, RightSign COVID-19 IgG/IgM Rapid Test Cassette, Genrui Novel Coronavirus (2019-nCoV) IgG/IgM test kit], their overall sensitivity remains significantly below WHO standards. Among 1,310 participants, Lumira Dx showed the highest sensitivity (61.4%), while MP SARS and Panbio achieved the highest specificity (98.5%). While these RDTs are reliable for confirming positive cases due to high specificity, their low sensitivity limits their effectiveness in ruling out infections, especially in asymptomatic individuals. The authors conclude that Nigeria needs locally developed diagnostics tailored to its specific environmental factors and circulating viral strains.
This study confirms that post-market surveillance is essential for maintaining diagnostic reliability as viruses evolve. Evaluation of six widely used COVID-19 point-of-care tests [four rapid antigen tests (Abbott Panbio, BTNX Rapid Response, SD Biosensor, and Quidel QuickVue) and two molecular tests (Abbott ID NOW and Lucira Check IT)] demonstrated that both rapid antigen and molecular assays maintained consistent clinical performance across various SARS-CoV-2 variants, including Omicron XBB.1.5. These findings validate the continued use of decentralized testing and reinforce confidence in these tools despite the emergence of new viral mutations.
Diagnostic performance of rapid antigen testing for SARS-CoV-2: the COVid-19 AntiGen (COVAG) extension study.
Field evaluations of four SARS-CoV-2 rapid antigen tests during SARS-CoV-2 Delta variant wave in South Africa.
This study demonstrates that in resource-limited settings like Mozambique, Ag-RDTs are a highly cost-effective alternative to RT-PCR, costing approximately three times less per test ($11.60 vs. $39.20). Medical supplies emerged as the primary cost driver, accounting for over 50% of total expenses, while the impact of personnel and overhead costs remained secondary. The findings suggest that the most effective way for governments in LMICs to reduce testing expenditures is to focus on lowering the cost of medical supplies rather than shifting labor cadres. Ultimately, integrating affordable Ag-RDTs into national screening strategies provides a sustainable and efficient pathway for managing pandemic diagnostic needs in resource-scarce environments.
Sensitivity analysis of rapid antigen tests for the Omicron SARS-CoV-2 variant detection from nasopharyngeal swab samples collected in Santiago of Chile.
Field evaluation of the performance of seven Antigen Rapid diagnostic tests for the diagnosis of SARs-CoV-2 virus infection in Uganda.
Diagnostic Performance of Six Rapid Antigen Tests for SARS-CoV-2.
Diagnostic Performance of Rapid Antigen Testing for SARS-CoV-2: The COVid-19 AntiGen (COVAG) study.
Non-SARS-CoV-2 respiratory viral detection and whole genome sequencing from COVID-19 rapid antigen test devices: a laboratory evaluation study.
Rapid antigen test as a screening tool for SARS-CoV-2 infection: Head-to-head comparison with qRT-PCR in Ethiopia.
The sensitivity and specificity of Abbott Panbio™ COVID 19 Ag Rapid test in the context of four SARS-CoV-2 variants.
Saliva sampling and its direct lysis is an excellent option for SARS-CoV-2 diagnosis in paediatric patients: comparison with the PanBio COVID-19 antigen rapid test in symptomatic and asymptomatic children.
Diagnostic evaluation of Panbio™ antigen rapid diagnostic test for SARS-CoV-2: A systematic review and meta-analysis.
Diagnostic accuracy of Panbio™ rapid antigen test for SARS-CoV-2 in paediatric population.
COVID-19 self-testing using antigen rapid diagnostic tests: Feasibility evaluation among health-care workers and general population in Malawi.
Retrospective and prospective studies evaluating the performance of the SARS-Cov-2 "AQ+ COVID-19 Ag Rapid Test" from InTec on symptomatic and non-symptomatic patients.
"This data highlights the rise and diversification of SARS-CoV-2 omicron variants over the course of 2022 and demonstrate that each of the 5 tested assays can detect the breadth of omicron variants circulating globally."
Evaluation of the performance of Abbott Panbio™ COVID-19 antigen rapid diagnostic test for the detection of severe acute respiratory syndrome coronavirus 2 at Harar, Eastern Ethiopia.